Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
Clinical trial NCT01961609 · COMPLETED
Trial details
- NCT number
- NCT01961609
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-10-09
- Primary completion
- 2016-07-12
- Enrollment
- 235
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.